These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1401 related items for PubMed ID: 17000959

  • 21. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 22. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 23. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study.
    Clin Ther; 2009 Aug 22; 31(8):1724-36. PubMed ID: 19808131
    [Abstract] [Full Text] [Related]

  • 24. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
    Mult Scler; 2010 Apr 22; 16(4):450-4. PubMed ID: 20150398
    [Abstract] [Full Text] [Related]

  • 25. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
    Acta Neurol Scand; 2006 Apr 22; 113(4):241-7. PubMed ID: 16542163
    [Abstract] [Full Text] [Related]

  • 26. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
    Mult Scler; 2010 May 22; 16(5):588-96. PubMed ID: 20167591
    [Abstract] [Full Text] [Related]

  • 27. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 28. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M, CHAMPIONS Study Group.
    Neurology; 2006 Mar 14; 66(5):678-84. PubMed ID: 16436649
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
    J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
    [Abstract] [Full Text] [Related]

  • 30. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 15; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 31. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 15; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 32. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group.
    J Neurol Sci; 2005 Dec 15; 239(1):67-74. PubMed ID: 16169561
    [Abstract] [Full Text] [Related]

  • 33. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS, Rice GP, Alsop JC, PRISMS Study Group.
    Neurology; 2005 Jul 12; 65(1):48-55. PubMed ID: 16009884
    [Abstract] [Full Text] [Related]

  • 34. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
    [Abstract] [Full Text] [Related]

  • 35. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb 07; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 36. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, Hansen T, Danish Multiple Sclerosis Group.
    Neurology; 2006 Apr 11; 66(7):1056-60. PubMed ID: 16510769
    [Abstract] [Full Text] [Related]

  • 37. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 11; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 38. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 39. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
    Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L, European IFN-1a in Relapsing MS Dose Comparison Trial Study Group.
    Neurology; 2005 Jan 25; 64(2):236-40. PubMed ID: 15668419
    [Abstract] [Full Text] [Related]

  • 40. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 25; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 71.